Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR8 | P51685 | 2/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | ITGA4 | P13612 | 3/20 | 0.33 |
| ▸ | ITGB7 | P26010 | 3/20 | 0.33 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.33 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
| ▸ | SOAT1 | P35610 | 2/20 | 0.32 |
| ▸ | CCR3 | P51677 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.30 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2471510 | 0.88 | SOAT1 (0.34) | CCR8KCNH2ITGA4ITGB7ITGB1 | |
| SCHEMBL2468085 | 0.85 | SOAT1 (0.32) | ITGA4ITGB7ITGB1SOAT1CCR3 | |
| SCHEMBL2469967 | 0.84 | SOAT1 (0.35) | SOAT1SLC6A9 | |
| SCHEMBL2492124 | 0.84 | SOAT1 (0.32) | ITGA4ITGB7ITGB1SOAT1CCR3 | |
| SCHEMBL2701752 | 0.82 | ALDH1A1 (0.41) | ITGA4ITGB7ITGB1OPRM1SLC6A9 | |
| SCHEMBL2471159 | 0.80 | SLC6A9 (0.36) | CCR8KCNH2ITGA4ITGB7ITGB1 | |
| SCHEMBL2471272 | 0.80 | PNLIP (0.34) | SOAT1 | |
| SCHEMBL2468487 | 0.79 | ALDH1A1 (0.33) | CCR8KCNH2ITGA4ITGB7ITGB1 | |
| SCHEMBL2470579 | 0.79 | KMT2A (0.34) | ITGA4ITGB7ITGB1CCR3SLC6A9 | |
| SCHEMBL2469411 | 0.79 | SMN1; SMN2 (0.34) | CCR8KCNH2ITGA4ITGB7ITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2228065-B1 | Heterocyclo inhibitors of potassium channel function | BRISTOL MYERS SQUIBB CO (US) | 2012-12-26 | — | — | EP | disclosed |
| EP-1501467-B1 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL MYERS SQUIBB CO (US) | 2012-05-09 | — | — | EP | disclosed |
| EP-2371366-A1 | Heterocyclo inhibitors of potassium channel function | Bristol-Myers Squibb Company (US) | 2011-10-05 | — | — | EP | disclosed |
| EP-2228065-A2 | Heterocyclo inhibitors of potassium channel function | Bristol-Myers Squibb Company (US) | 2010-09-15 | — | — | EP | disclosed |
| US-20090312307-A1 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2009-12-17 | — | — | US | disclosed |
| US-7005436-B2 | Heterocyclo inhibitors of potassium channel function | BRISTOL MYERS SQUIBB COMPANY (US) | 2006-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312307-A1 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | KCNJ2, KCNH2, KCNQ5 | CCR8 4685/4885KCNH2 2/4885ITGA4 4566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.